These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27185544)

  • 1. Gene therapies: the challenge of super-high-cost treatments and how to pay for them.
    Carr DR; Bradshaw SE
    Regen Med; 2016 Jun; 11(4):381-93. PubMed ID: 27185544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Need for an incentive-based reimbursement policy toward quality care for dialysis patient management.
    Hidai H
    Kidney Int; 2000 Jul; 58(1):363-73. PubMed ID: 10886583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.
    Coyle D; Durand-Zaleski I; Farrington J; Garrison L; Graf von der Schulenburg JM; Greiner W; Longworth L; Meunier A; Moutié AS; Palmer S; Pemberton-Whiteley Z; Ratcliffe M; Shen J; Sproule D; Zhao K; Shah K
    Eur J Health Econ; 2020 Dec; 21(9):1421-1437. PubMed ID: 32794011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Adv Exp Med Biol; 2017; 1031():221-231. PubMed ID: 29214575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.
    Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2017; 5(1):1355203. PubMed ID: 28839525
    [No Abstract]   [Full Text] [Related]  

  • 6. Paying for quality not quantity: a wisconsin health maintenance organization proposes an incentive model for reimbursement of chiropractic services.
    Pursel KJ; Jacobson M; Stephenson K
    J Manipulative Physiol Ther; 2012 Jul; 35(6):472-6. PubMed ID: 22926019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Realizing the Potential of Gene Therapies for Rare and Ultra-Rare Inherited Diseases.
    Booth C; Aiuti A
    Hum Gene Ther; 2023 Sep; 34(17-18):776-781. PubMed ID: 37624746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insuring patient access and affordability for treatments for rare and ultrarare diseases: a policy statement of the American College of Medical Genetics and Genomics.
    ACMG Board of Directors
    Genet Med; 2018 Nov; 20(11):1303-1304. PubMed ID: 30131518
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolving provider payment models and patient access to innovative medical technology.
    Long G; Mortimer R; Sanzenbacher G
    J Med Econ; 2014 Dec; 17(12):883-93. PubMed ID: 25221929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative health reform models: pay-for-performance initiatives.
    Glickman SW; Peterson ED
    Am J Manag Care; 2009 Dec; 15(10 Suppl):S300-5. PubMed ID: 20088634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments.
    Dabbous M; Toumi M; Simoens S; Wasem J; Saal G; Wang Y; Osuna JLH; François C; Annemans L; Graf von der Schulenburg JM; Sola-Morales O; Malone D; Garrison LP
    Health Policy; 2022 Jan; 126(1):49-59. PubMed ID: 34863529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare disease patient/caregiver perspective on fair pricing and access to gene-based therapies.
    White W
    Gene Ther; 2019 Nov; 27(10-11):474-481. PubMed ID: 31723211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies.
    Horrow C; Kesselheim AS
    Health Aff (Millwood); 2023 Nov; 42(11):1532-1540. PubMed ID: 37931198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Funding therapies for rare diseases: an ethical dilemma with a potential solution.
    Taylor C; Jan S; Thompson K
    Aust Health Rev; 2018 Feb; 42(1):117-119. PubMed ID: 28202130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards novel reimbursement models for expensive advanced therapy medicinal products (ATMPs).
    Picecchi D; Bertram K; Brücher D; Bauer M
    Swiss Med Wkly; 2020 Dec; 150():w20355. PubMed ID: 33378542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments.
    Salzman R; Cook F; Hunt T; Malech HL; Reilly P; Foss-Campbell B; Barrett D
    Mol Ther; 2018 Dec; 26(12):2717-2726. PubMed ID: 30414722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of innovative payment mechanisms for gene therapies in Europe and the USA.
    Jørgensen J; Kefalas P
    Regen Med; 2021 Apr; 16(4):405-422. PubMed ID: 33847163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current State of Value-Based Purchasing Programs.
    Chee TT; Ryan AM; Wasfy JH; Borden WB
    Circulation; 2016 May; 133(22):2197-205. PubMed ID: 27245648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.